Skip to content

Post-Market Clinical Follow-Up onTVT EXACT® Continence System

A Long Term Prospective Post Market Clinical Follow-up (PMCF) of the GYNECARE TVT EXACT® Continence System for the Treatment of Stress Urinary Incontinence

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04829994
Enrollment
198
Registered
2021-04-02
Start date
2021-07-07
Completion date
2035-09-30
Last updated
2026-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress Urinary Incontinence

Keywords

GYNECARE TVT EXACT® Continence System, SUI

Brief summary

The objective of this single arm, post market, clinical study is to evaluate the performance of Gynecare TVT EXACT® Continence System in women undergoing retropubic mid-urethral sling surgery for Stress Urinary Incontinence (SUI).

Interventions

DEVICEIntervention

There is no intervention, beyond necessary clinical care, in this study. The surgical procedures being performed within the study are identical to the surgical procedures subjects would receive as part of SOC.

Sponsors

Ethicon, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Subjects who satisfy all of the following criteria will be considered eligible for enrollment in this study: 1. Stress urinary incontinence symptoms 2. Stress urinary incontinence confirmed by diagnostic evaluation of a cough stress test 3. Female subjects ≥ 21 years of age requiring treatment of SUI 4. Desired surgical correction of stress urinary incontinence using a synthetic pubo-urethral vaginal sling 5. Planned surgery for primary stress incontinence without concomitant prolapse surgery 6. Patient able and willing to participate in follow-up 7. Subject or authorized representative has signed the approved informed consent

Exclusion criteria

Subjects meeting any of the following criteria will be considered not eligible for enrollment in this study: 1. Physical or psychological condition which would impair study participation or are unwilling or unable to participate in all required study visits and are unable to complete the questionnaires 2. Any pre-operative or intra-operative findings identified by the surgeon that may preclude the use of study product 3. History of previous synthetic, biologic or fascial pubo-urethral sling 4. Pregnancy or plans for future pregnancy 5. History of bleeding diathesis or current anti-coagulation therapy which cannot be suspended peri-operatively according to site's standard practice. 6. Current genitourinary fistula or urethral diverticulum 7. Reversible cause of incontinence (i.e. drug effect) 8. Contraindication to surgery

Design outcomes

Primary

MeasureTime frameDescription
Cough Stress Test (CST) Assessment ChangePost-surgery through study completion, approximately 5-10 yrsObjective cure of Stress Urinary Incontinence (SUI) (treatment success) sproximately 5-10 years after surgery, defined as a negative CST

Secondary

MeasureTime frameDescription
Patient Global Impression of Improvement (PGI-I)Post-surgery through study completion, approximately 10 yrs
International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF)Baseline and post-surgery through study completion, approximately 10 yrs
Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12)Baseline and post-surgery through study, approximately 10 yrs completion
Wong-Baker FACES® Pain Rating ScalePost-surgery through study completion, approximately 10 yrsTo assess pain on a scale from 0 (no pain) to 10 (worst pain) related to study device or procedure

Countries

Austria, Denmark, France, Germany, Sweden, United States

Contacts

STUDY_DIRECTORMartin Weisberg, MD

Ethicon, Inc.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 7, 2026